Opthea Limited (NASDAQ:OPT – Get Free Report)’s share price traded up 8.8% during mid-day trading on Wednesday . The company traded as high as $2.85 and last traded at $2.85. 14,931 shares were traded during trading, a decline of 37% from the average session volume of 23,518 shares. The stock had previously closed at $2.62.
Opthea Trading Up 8.8 %
The business’s 50-day simple moving average is $2.13 and its 200-day simple moving average is $2.93.
Opthea Company Profile
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Further Reading
- Five stocks we like better than Opthea
- Insider Trades May Not Tell You What You Think
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- High Flyers: 3 Natural Gas Stocks for March 2022
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
